Lilly's Zepbound Falters, Foundayo Struggles

Eli Lillys stock dropped by 3.5% today, closing at $883.89, due to lower prescription fills for their injectable weight-loss drug Zepbound and underwhelming performance of their new oral obesity pill Foundayo. Despite this, investors remain optimistic about Lillys long-term prospects, especially after their recent acquisition of Centessa Pharmaceuticals for $7.8 billion to expand into neuroscience and sleep disorders. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c961015038a5ca6d